Home Overview Research Programs Shared Facilities News & Outreach Technology Transfer Employment About PHRI

 
Scientific Overview Research Interest Summary Principal Investigators    Yuri Bushkin, Ph.D.
   Theresa Chang, Ph.D.
   Neeraj Chauhan, Ph.D.
   Véronique Dartois, Ph.D.
   Thomas Dick, Ph.D.
   Karl Drlica, Ph.D.
   David Dubnau, Ph.D.
   Eliseo A. Eugenin, Ph.D.
   Marila Gennaro, M.D.
   Fred Kramer, Ph.D.
   Barry Kreiswirth, Ph.D.
   Min Lu, Ph.D.
   Leonard Mindich, Ph.D.
   Arkady Mustaev, Ph.D.
   Jyothi Nagajyothi, Ph.D.
   David Perlin, Ph.D.
   Abraham Pinter, Ph.D.
   Marcela Rodriguez, Ph.D.
   Lanbo Shi, Ph.D.
   Selvakumar Subbian, Ph.D.
   Sanjay Tyagi, Ph.D.
   Christopher Vinnard, M.D.
   Chaoyang Xue, Ph.D.
   Xilin Zhao, Ph.D.

   Research Faculty
   Liang Chen, Ph.D.
   Eugenie Dubnau, Ph.D.
   Jeanette Hahn, Ph.D.
   Salvatore Marras, Ph.D.
   Yanan Zhao, Ph.D.

Emeritus Faculty Recent Publications
 
Christopher Vinnard, M.D., M.P.H., M.S.C.E.

Research Summary  |  Selected Publications  |  C.V.
 

Public Health Research Institute Center and
Department of Medicine
New Jersey Medical School - Rutgers, The State University of New Jersey
225 Warren Street
Newark, New Jersey 07103

Phone: (973) 854-3430
e-mail: cv274@njms.rutgers.edu


Research Summary

I am an infectious disease physician with dual training in clinical epidemiology and pharmacometrics, supported by an NIH Career Development award. My clinical interest in tuberculosis began during my residency at NYU/Bellevue Hospital, and I currently see patients at the Global Tuberculosis Institute in Newark, NJ. This background has steered my interest in understanding the patient factors that relate to variability in the pharmacokinetics and the pharmacodynamics of anti-infective therapies, with a particular focus on tuberculosis and nontuberculous mycobacterial (NTM) infections. The program has four areas of interest as discussed below.

Immune activation, gut damage, and pharmacokinetic variability of anti-tuberculosis drugs in HIV/tuberculosis patients. Current efforts in our laboratory are focusing on the expression and activity of membrane drug transporters and key drug metabolizing enzymes relevant for anti-TB therapies, combined with clinical studies of anti-tuberculosis drug pharmacokinetics in HIV-infected patients. The goal of this work is to link the observations of low anti-TB drug serum exposures in patients with HIV infection or other chronic diseases with a mechanistic understanding of the regulation of drug transporters and metabolizing enzymes in the context of inflammatory or metabolic disease.

Developing a point-of-care assay for therapeutic drug monitoring during tuberculosis treatment in resource limited settings. We are evaluating urine colorimetry as a simple platform for measuring anti-tuberculosis drug exposure, which could be a low-cost approach appropriate for high burden settings where blood-based methods of therapeutic drug monitoring would not be feasible.

The role of initial drug resistance in the outcomes of tuberculous meningitis. Meningitis is the most devastating manifestation of tuberculosis. I have led investigations of the epidemiology of drug resistant tuberculous meningitis, using surveillance data collected by the National Tuberculosis Surveillance System at the Centers for Disease Control and Prevention. More recently, I have developed a collaboration with the New York City Department of Health and Mental Hygiene, linking of the tuberculosis registry with the vital statistics database to examine the long-term mortality of tuberculous meningitis patients, both during and after treatment.

Clinical epidemiology of nontuberculous mycobacterial infections in a high prevalence setting. In collaboration with investigators at the Perelman School of Medicine at the University of Pennsylvania, we are building a clinical cohort of nontuberculous mycobacterial patients from the greater Philadelphia region, which has one of the highest prevalence rates of NTM infections in the United States. The goals of this work are to pursue fundamental questions regarding acquisition and progression of disease, including the role of genetic and immunologic factors.




Selected Publications


Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. 2016. Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014. Annals of the American Thoracic Society. In press.

Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya J, Gumbo T, Peloquin CA, Bisson GP, Vinnard C. 2016. Urine Colorimetry to Detect Low Rifampin Exposure During Tuberculosis Therapy: A Proof-of-Concept Study. BMC Infectious Diseases. doi: 10.1186/s12879-016-1576-1.

Arif N, Yousfi S, Vinnard C. 2016. Deaths from Necrotizing Fasciitis in the United States, 2003-2013. Epidemiology and Infection. 144(6): 1338-44.

Longworth SA, Blumber EA, Barton TD, Vinnard C. 2015. Nontuberculous mycobacterial infections after solid organ transplantation: a survival analysis. Clinical Microbiology and Infection. 21(1):43-7. PMID 25636926.

Zivich S, Cauterucci M, Allen S, Vetter M, Vinnard C. 2015. Long-term virologic outcomes following bariatric surgery in patients with HIV. Obesity Research and Clinical Practice. 9(6): 633-5.

Longworth S, Vinnard C, Sims K, Lee I, Barton T, Blumberg EA. 2014. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transplant Infectious Diseases. 16(1):76-83.

Vinnard C, Wileyto EP, Bisson G, Winston C. 2013. First use of multiple imputation with the National Tuberculosis Surveillance System. Epidemiology Research International. doi:pii:875234.

Vinnard C, Gopal A, Linkin DR, Maslow J. 2013. Isoniazid toxicity among an older veteran population: a retrospective cohort study. Tuberculosis Research and Treatment. 2013;2013:549473.

Vinnard C, Linkin DR, Behrman A. 2012. Current Approach to Latent Tuberculosis Diagnosis and Treatment Among Medical Center Occupational Health Physicians. Infection Control and Hospital Epidemiology. 33(12):126205.

Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. 2011. Multidrug resistant tuberculous meningitis in the United States, 1993-2005. Journal of Infection. 63(3):240-2.

Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. 2011. Isoniazid resistant tuberculous meningitis, United States, 1993-2005. Emerging Infectious Diseases. 17(3): 539-42.

Vinnard C, Winston C, Wileyto E, Macgregor R, Bisson G. 2010. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. British Medical Journal. 341: c4451.

Vinnard C, Macgregor R. 2009. Tuberculous meningitis in the HIV-infected individual. Current HIV/AIDS Reports. 6(3): 139-45.






C.V.


Please follow this link to download a PDF copy of Christopher Vinnard's CV.




 
     Copyright © 2017 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101